Green Cross has a growing portfolio of cell therapy projects
Singapore: Green Cross, South Korean biopharmaceutical company, is expanding its manufacturing base by building a new cell therapy manufacturing facility in Guizhou province of China. The new manufacturing site will address the cellular therapeutic industry's demand for clinical studies and commercial supply.
Green Cross has a growing portfolio of approved and clinical stage cell therapy projects including T cell, NK cell, dendritic cell and stem cells. Cell therapy products are an increasingly significant tool in the treatment of serious diseases.
"Our investment reflects the strength of our business and the increasingly important role that cell therapy will play in Green Cross' future," said Dr BG Rhee, president, Green Cross. "Over the last 20 years, Green Cross has maintained a significant manufacturing facility and sales forces for plasma fractionation business in China, and we look forward to building on that legacy through this business expansion."
